The Hepatix Extracorporeal Liver Assist Device: Initial Clinical Experience

Artificial Organs - Tập 18 Số 5 - Trang 390-396 - 1994
Norman Sussman1, Gardar T. Gislason2, Carol Conlin2, James H. Kelly2
1Baylor College of Medicine, Houston, Texas, U.S.A.
2Hepatix Incorporated, Houston, Texas, U.S.A.

Tóm tắt

Abstract: Eleven patients were treated with the Hepatix extracorporeal liver assist device (ELAD) between June 1991 and August 1993. The first 2 patients were treated according to Food and Drug Administration guidelines (“Emergency Use of Unapproved Medical Devices,” October 22, 1985), and the remaining 9 were treated according to an Investigational Device Exemption (IDE). The goal of the study was to establish the short‐term safety of ELAD therapy, with a focus on acute medical complications such as hemodynamic instability, complement activation, and deterioration of vital organ function. As secondary goals, the metabolic capacity of ELAD cartridges and their clinical impact were assessed. Treatment was considered successful if the patient recovered sufficient liver function to survive weaning from the ELAD or was stabilized until orthotopic liver transplantation was performed. No short‐term safety problems were associated with ELAD use. In addition, metabolic support was documented in 10 of the 11 patients, and 6 patients reached a successful end‐point. The Hepatix ELAD is safe, and it provides measurable metabolic support in patients with late‐stage liver failure. This pilot study provides the impetus to perform controlled trials of ELAD therapy in the treatment of various types of end‐stage liver disease.

Từ khóa


Tài liệu tham khảo

10.1159/000170114

10.1002/hep.1840170216

10.1111/j.1525-1594.1992.tb00296.x

10.1016/0022-4804(92)90253-V

10.1002/hep.1840150225

10.1002/hep.1840160112

10.1111/j.1525-1594.1993.tb00381.x

SussmanNL FinegoldMJ BarishJP KellyJH.Recovery from syncytial giant‐cell hepatitis following treatment with an extracorporeal liver assist device.Am J Gastroenterol1994(in press).

10.1016/0016-5085(89)90081-4

GislasonGT LobdellDD KellyJH SussmanNL.A pumping system for implementation of extracorporeal organ support.Artif Organs1994(in press).

Tygstrup N., 1966, Determination of the hepatic elimination capacity of galactose by a single injection, Scand J Clin Lab Invest, 185, 118

10.1016/S0378-4347(00)81538-8

10.1016/S0021-9673(01)94639-4

Siegelman ES, 1992, Recovery of native liver after heterotopic liver transplantation for fulminant hepatic failure: MR studies, J Comput Assist Tomogr, 16, 152

10.1016/0092-8674(91)90615-6

Thông tin
Thông tin xuất bản

Artificial Organs

Tập 18 Số 5

390-396

Thông tin tác giả